World Heart Day – September 29, 2025

World Heart Day 2025 is a global initiative dedicated to raising awareness about cardiovascular health. It highlights the importance of healthy living to prevent heart disease and stroke.  

Biomarkers have revolutionized on how heart diseases are diagnosed and treated. Ongoing research on newer exploratory protein biomarkers may shed light into the complex mechanisms that drive the disease process.

Biomedica offers a range of quality ELISA assay kits for your clinical and preclinical research:

World Heart Day – September 29, 2025

Biomarkers for Heart Disease:  NT-proBNP, NT-proAN`P, Big Endothelin-1, FGF23, LRG1

NT-proBNP  is a biomarker used to assess heart failure and measure the severity of cardiac dysfunction. Elevated levels of NT-proBNP indicate increased stress on the heart (1).

NT-proANP (N-terminal pro-atrial natriuretic peptide) is a biomarker released by the heart in response to atrial stretch and increased blood volume. It is used clinically to assess heart failure and identify cardiac stress, aiding in diagnosis and management of cardiovascular conditions (2).

Big Endothelin-1 is an inactive precursor of endothelin-1, a potent vasoconstrictor involved in regulating blood vessel tone and blood pressure. Elevated levels of Big Endothelin-1 are associated with cardiovascular diseases such as hypertension and heart failure (3).

FGF23 (Fibroblast Growth Factor 23) is a hormone primarily involved in regulating phosphate metabolism and vitamin D levels. It helps maintain mineral balance by reducing phosphate reabsorption in the kidneys and suppressing vitamin D activation. Elevated FGF23 levels are linked to cardiovascular disease and chronic kidney disease (4).

Leucine-rich alpha-2-glycoprotein (LRG) is a plasma protein involved in immune response and inflammation. It plays a role in modulating immune cell activity and has been studied as a potential biomarker for various inflammatory and infectious conditions (5).

 

Biomedica offers a range of quality ELISA assay kits for your clinical and preclinical research:

-NT-proBNP (Cat. No. BI-1204), Rat NT-proBNP (Cat. No. BI-1204R)

-NT-proANP (Cat. No. BI-20892) (human  and non-human (rat, mouse.. ) use

-Big Endothelin-1 (Cat. No. BI-20082H)

-FGF23 intact (Cat. No. BI-20700)

-FGF23 c-terminal (Cat. No.  BI-20702)

-LRG (Cat. No. BI-LRG)

 

Literature 

1. BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis. Ammar LA, Massoud GP, Chidiac C, Booz GW, Altara R, Zouein FA. Heart Fail Rev. 2025 Jan;30(1):45-54. doi: 10.1007/s10741-024-10442-6. Epub 2024 Oct 7. PMID: 39373821; PMCID: PMC12002167.
2. Prognostic value of NT-proANP levels on major cardiovascular outcomes in a 31-year follow-up study depends on baseline morbidity. Sakko S, Perkiömäki J, Ylitalo A, Huikuri H, Ukkola O, Koivunen P, Tapio J. Sci Rep. 2025 May 28;15(1):18660. doi: 10.1038/s41598-025-03819-6. PMID: 40436983; PMCID: PMC12119872.
3. Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure. Wang J, Feng J, Tse G, Zhai M, Huang Y, Zhou Q, Zhuang X, Liu H, Zhang Y, Zhang J. Korean Circ J. 2025 Aug;55(8):705-717. doi: 10.4070/kcj.2024.0354. Epub 2025 Apr 11. PMID: 40345830; PMCID: PMC12314060.
4. Network Interactions of Circulating FGF23, HRG-HMGB1, and Cardiac Disease in CKD. Perwad F, Akwo EA, Singhal A, Vartanian N, Suva LJ, Friedman PA, Robinson-Cohen C. J Am Soc Nephrol. 2025 Apr 16. doi: 10.1681/ASN.0000000710. Epub ahead of print. PMID: 40238264.
5. Leucine-rich alpha-2 glycoprotein as a potential biomarker for large vessel vasculitides. Umezawa N, Mizoguchi F, Maejima Y, Kimura N, Hasegawa H, Hosoya T, Fujimoto M, Kohsaka H, Naka T, Yasuda S. Front Med (Lausanne). 2023 May 5;10:1153883. doi: 10.3389/fmed.2023.1153883. PMID: 37215715; PMCID: PMC10196172.